Chong Kun Dang scores its 'largest ever' $1.3B deal with Novartis for CKD-510

South Korea’s Chong Kun Dang Pharmaceuticals Corp. said that it struck a deal potentially worth $1.3 billion with Swiss pharma giant Novartis AG for its CKD-510 candidate for neurological and cardiovascular diseases, propelling its shares upward 26.11% by market closing of Nov. 6. With the “largest ever” deal in its history, shares of the Seoul-based pharmaceutical (KOSPI:185750) on the Korea Exchange rose by 26.11%, or ₩26,500, closing at ₩128,000 ($98.70).

Related Keywords

South Korea , Seoul , Soult Ukpyolsi , Switzerland , Swiss , Korea , , Korea Exchange , Korea Chong Kun Dang Pharmaceuticals Corp , Chong Kun Dang Pharmaceuticals , Chong Kun Dang Pharmaceutical Corp , Charcot Marie Tooth Disease , Novartis Ag , Ckd 510 , Hdac6 Inhibitors , Atrial Fibrillation , Heart Disease , Nesbell , Duvie ,